5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists

Details 5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists 5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists

2002-12-18

2008-03-11

Tucker, Zachary C (Department: 1624)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S255060, C544S405000, C544S406000, C544S408000

Reexamination Certificate

active

07342019

ABSTRACT:
The present invention relates to compounds of formula (I), and pharmaceutically acceptable salts, prodrugs, solvates and crystalline forms thereof, in which R1and R2independently represent: a C1-6alkyl group; an optionally substituted (amino)C1-4alkyl-group; an optionally substituted non-aromatic C3-15carbocyclic group; a (C3-12cycloalkyl)C1-3alkyl-group; a group —(CH2)r(phenyl)sin which r is 0, 1, 2, 3 or 4, s is 1 when r is 0 otherwise s is 1 or 2 and the phenyl groups are optionally independently substituted by Z; naphthyl; anthracenyl; an optionally substituted saturated 5 to 8 membered heterocyclic group containing one nitrogen and optionally one of the following: oxygen, sulphur or an additional nitrogen; 1-adamantylmethyl; a group —(CH2)tHet in which t is 0, 1, 2, 3 or 4, and the alkylene chain is optionally substituted and Het represents an optionally substituted aromatic heterocycle; or R1represents H and R2is as defined above; or R1and R2together with the nitrogen atom to which they are attached represent a saturated optionally substituted 5 to 8 membered heterocyclic group as defined above; X is CO or SO2; Y is absent or represents NH optionally substitututed by a C1-3alkyl group; R3and R4independently represent phenyl, thienyl or pyridyl substituted by Z; Z represents a C1-3alkyl group, a C1-3alkoxy group, hydroxy, halo, trifluoromethyl, trifluoromethylthio, trifluoromethoxy, trifluoromethylsulphonyl, nitro, amino, mono or di C1-3alkylamino, mono or di C1-3alkylamido, C1-3alkylsulphonyl, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkyl carbamoyl, sulphamoyl and acetyl; and R5is H, a C1-3alkyl group, a C1-3alkoxymethyl group, trifluoromethyl, a hydroxyC1-3alkyl group, C1-3alkoxycarbonyl, carboxy, cyano, carbamoyl, mono or di C1-3alkylcarbamoyl, acetyl, or hydrazinocarbonyl of formula —CONHNRaRb; with the provisos; and processes for preparing such compounds, their use in the treatment of obesity, psychiatric and neurological disorders, to methods for their therapeutic use and to pharmaceutical compositions containing them.

REFERENCES:
patent: 458 361 (1968-06-01), None
patent: 27 36 230 (1978-02-01), None
patent: 0 397 859 (1990-11-01), None
patent: 0 656 354 (1995-06-01), None
patent: WO-92/02513 (1992-02-01), None
Al-Dabbagh and Smith, “Species differences in oxidative drug metabolism: some basic considerations.” Archives of toxicology. Supplement. Archiv fur Toxikologie. supplement, vol. 7, pp. 219-231 (1984).
Hans Bundgaard, Design of Prodrugs, p. 1. © 1985 Elsevier Science Publishers.
Richard B. Silverman, The Organic Chemistry of Drug Design and Drug Action, pp. 352-400. © 1992 Academic Press, Inc.
Vippagunta et al, “Crystalline Solids” Advanced Drug Delivery Reviews, vol. 48, pp. 3-26 (2001).
Gavezzotti, “Are Crystal Structures Predictable?” Accounts of Chemical Research, vol. 27, pp. 309-314 (1994).
Taylor et al, “Pteridines. X. A New Approach to the Synthesis of Pteridines” Journal of the American Chemical Society, vol. 75(8), pp. 1904-1908 (1953).
Boon and Bratt, “Pteridines. V. Derivatives of 1,4-dihydro-1- and 3,4-dihydro-3-methyl-6,7-diphenylpteridine” Journal of the Chemical Society, pp. 2159-2161 (1957).
Martin, J.C. “‘Frozen’ Transition States: Pentavalent Carbon et al” Science, vol. 221(4610), pp. 509-514 (Aug. 5, 1983).
Brittain, H. G. “X-Ray Powder Diffraction of Pharmaceutical Materials” American Pharmaceutical Review, vol. 5(1), pp. 74, 76 78 and 80 (2002).
Marzo et al, “Leptin-regulated endocannbinoids are involved in maintaining food intake” Nature, vol. 410, pp. 822-825 (Apr. 12, 2001).
Howlett et al., “Azido- and Isothiocyanato-Substituted Aryl Pyrazoles Bind Covalenty to the CB1Cannabinoid Receptor and Impair Signal Transduction,” Journal of Neurochemistry 74(5):2174-2181 (2000).

Affiliated with

Also associated with

Rating

5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with 5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and 5, 6-diaryl-pyrazine-2-amide derivatives as CB 1 antagonists will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3968225